Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | DHFR | P00374 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9744353 | 1.00 | SIGMAR1 (0.47) | SIGMAR1LMNALTA4HTSHRDHFR | |
| Bromide SCHEMBL28805308 | 0.98 | SIGMAR1 (0.46) | SIGMAR1LMNALTA4HTSHRDHFR | |
| SCHEMBL2982806 | 0.98 | TSHR (0.46) | SIGMAR1LMNALTA4HTSHRDHFR | |
| Hydrochloric Acid SCHEMBL2978407 | 0.96 | LMNA (0.46) | SIGMAR1LMNALTA4HTSHRDHFR | |
| SCHEMBL15094370 | 0.94 | TSHR (0.46) | SIGMAR1LTA4HTSHRDHFRSLC6A3 | |
| SCHEMBL6620777 | 0.86 | HRH3 (0.53) | LTA4HHRH3 | |
| SCHEMBL10382845 | 0.81 | ALDH1A1 (0.41) | TSHRDHFRRAB9ANPC1 | |
| SCHEMBL28598923 | 0.80 | TSHR (0.50) | SIGMAR1LMNATSHRSLC6A3 | |
| SCHEMBL23279497 | 0.80 | KMT2A (0.53) | SIGMAR1LMNALTA4HTSHRHPGD | |
| SCHEMBL20892082 | 0.80 | MC4R (0.53) | SIGMAR1LTA4HTSHRHRH3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638614-A | Recycling method of waste liquid generated in production of avibactam intermediate | 德州宏海医药科技有限公司 | 2025-03-18 | — | — | CN | claimed |
| EP-0134124-B1 | PIPERIDINE DERIVATIVES | FORDONAL, S.A. (ES) | 1987-10-28 | — | — | EP | claimed |
| EP-0134124-A1 | Piperidine derivatives | FORDONAL, S.A. (ES) | 1985-03-13 | — | — | EP | claimed |
| EP-0015817-A1 | Piperidine derivatives, process for their preparation and their use in therapeutical compositions | METABIO-JOULLIE Société anonyme: (FR) | 1980-09-17 | — | — | EP | claimed |
| CN-111423430-B | Fluorescent probe and preparation method thereof | 中山大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-109689650-B | Benzamide derivatives P2X7 receptor antagonists containing phenoxypiperidine or benzyloxypiperidine and thiazole | 阿克萨姆股份公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-109689650-B | Benzamide derivatives P2X7 receptor antagonists containing phenoxypiperidine or benzyloxypiperidine and thiazole | 阿克萨姆股份公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-109689650-B | Benzamide derivatives P2X7 receptor antagonists containing phenoxypiperidine or benzyloxypiperidine and thiazole | 阿克萨姆股份公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-114989169-A | Preparation method of avibactam sodium | 哈药集团技术中心 | 2022-09-02 | — | — | CN | disclosed |
| CN-114989169-A | Preparation method of avibactam sodium | 哈药集团技术中心 | 2022-09-02 | — | — | CN | disclosed |
| EP-3507287-B1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS | AXXAM SPA (IT) | 2020-07-15 | — | — | EP | disclosed |
| US-10669267-B2 | Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2020-06-02 | — | — | US | disclosed |
| CN-1039415-A | New 1, the preparation method of 3-3-disubstituted piperidine derivatives | PFIZER (GB) | 1990-02-07 | — | — | CN | disclosed |
| EP-0134124-B1 | PIPERIDINE DERIVATIVES | FORDONAL, S.A. (ES) | 1987-10-28 | — | — | EP | disclosed |
| US-4550116-A | ANTIALLERGENS, CARDIOVASCULAR AND RESPIRATORY DISORDERS | FORDONAL, S.A. (ES) | 1985-10-29 | — | — | US | disclosed |
| EP-0077427-B1 | PIPERIDINE DERIVATIVES, THEIR PREPARATION AND USE IN MEDICINE | SYNTHELABO (FR) | 1985-05-22 | — | — | EP | disclosed |
| EP-0134124-A1 | Piperidine derivatives | FORDONAL, S.A. (ES) | 1985-03-13 | — | — | EP | disclosed |
| EP-0077427-A1 | Piperidine derivatives, their preparation and use in medicine | SYNTHELABO (FR) | 1983-04-27 | — | — | EP | disclosed |
| EP-0015817-A1 | Piperidine derivatives, process for their preparation and their use in therapeutical compositions | METABIO-JOULLIE Société anonyme: (FR) | 1980-09-17 | — | — | EP | disclosed |
| EP-0015817-A1 | Piperidine derivatives, process for their preparation and their use in therapeutical compositions | METABIO-JOULLIE Société anonyme: (FR) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669267-B2 | Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists | P2RX7, P2RX2, P2RX1 | SIGMAR1 555/4885LMNA 1301/4885LTA4H 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.